As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Inclisiran for reduction of low-density lipoprotein cholesterol.
This review discusses lipid-lowering therapy, RNA-targeting strategies, therapeutic indications, dosage and administration, and summaries of some of the key studies featuring Inclisiran.
Recommendations are included from Clinical Associate Professor David Sullivan, a physician/chemical pathologist in the Department of Chemical Pathology at Royal Prince Alfred Hospital.
Please login below to download this issue (PDF)